21 May 2009
Optimal MPA, MPAG levels at the early period after kidney transplantation as the key contributors to improving long-term outcomes
T Baczkowska, A Sadowska, J Majchrzak, A Perkowska-Ptasińska, Z Lewandowski, T Cieciura, J Pazik, E Ważna, E Nowacka Cieciura, A Chmura, M DurlikAnn Transplant 2009; 14(1): 22-22 :: ID: 880277
Abstract
Background: Suboptimal MPA, MPAG levels are associated with significant
increases in graft loss. Purpose: to assess the influence of MPA, MPAG - Co
levels on GFR level and histological changes in the protocol biopsies in kidney allograft recipients.
Material/Methods: In a prospective study of 42 low-risk patients receiving MMF,
prednisone and a low or normal CsA dose we performed histological assessment according to Banff'97 classification in protocol biopsies before Tx and then at 3, 12, 36 months after Tx, we also assessed GFR at 1, 3, 12, 36 and 60 months after Tx and MPA (ELISA), MPAG (HPLC/UV) Co levels at day 7 and at 1, 3, 12, 36 months after Tx. Statistical analysis was performed with the aid of Generalized Additive Models (SAS System) and Spearman correlation.
Results: We observed significant relationships between MPA, MPAG Co levels and the subclinical rejection episodes (SCR), ci, ct, ah, CAN in the protocol biopsies at 36 month after Tx. In detail: MPA Co level at day 7 after Tx below 1.5 μg/mL was associated with increased risk of SCR (pnl<0.03), ci ≥2 (pnl<0.05), CAN ≥2 (pnl <0.04) and with ah ≥2 (pnl<0.07). MPAG Co level at day 7 after Tx above 100-150 μg/mL was associated with decreased risk of ct ≥2 (pnl <0.01), ci ≥2 (pnl <0.04), CAN ≥2 (pnl <0.04). We also observed significant positive correlations between MPA Co level and negative significant correlations
between MPAG Co level at 1 month after Tx and GFR at 1, 3, 12 and 36 month after Tx.
Conclusions: Optimal MPA exposure in the early post-transplant period may improve renal graft outcomes
Keywords: Immunosuppression, Kidney Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






